Exelixis, Inc. (ticker: EXEL, exchange: NASDAQ Global Market (.O))
News Release -
10-Oct-2006
Exelixis Announces Exercise of Option to Purchase Additional Shares by UnderwritersSOUTH SAN FRANCISCO, Calif., Oct 10, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Exelixis,
Inc. (Nasdaq: EXEL) announced today that on October 9, 2006, the underwriters
exercised in full their option to purchase 1.5 million shares of common stock
associated with Exelixis' public stock offering that priced at $8.40 per
share, before underwriting discounts and commissions, on October 4, 2006. The
exercise of the option to purchase the additional shares increases the size of
the offering to a total of 11.5 million shares of common stock, resulting in
net proceeds to Exelixis of approximately $90.5 million.
Goldman, Sachs & Co. is acting as the sole book-running manager for the
offering. Cowen and Company, LLC is acting as the joint lead manager, and Banc
of America Securities LLC and Piper Jaffray & Co. are acting as co-managers
for the offering.
A registration statement relating to these securities has been filed with
and declared effective by the Securities and Exchange Commission. The offering
may be made only by means of a prospectus supplement and the accompanying
prospectus. Copies of the final prospectus supplement and the accompanying
prospectus may be obtained by sending a request to Goldman, Sachs & Co., Attn:
Prospectus Department, 85 Broad Street, New York, New York 10004, Fax:
212-902-9316 or Email at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, any of the securities, nor shall there be any
sale of these securities, in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state.
About Exelixis
Exelixis, Inc. is a biotechnology company dedicated to the discovery and
development of novel therapeutics that will potentially enhance the care and
lives of patients with cancer and other serious diseases.
SOURCE Exelixis, Inc.
Frank Karbe, Chief Financial Officer, +1-650-837-7565, or fkarbe@exelixis.com, or
Charles Butler, Director, Corporate Communications, +1-650-837-7277, or
cbutler@exelixis.com, both of Exelixis, Inc.
http://www.exelixis.com/
|
Exelixis, Inc.
